|146.38||+1.81||+1.25%||Vol 4.78M||1Y Perf -11.70%|
|Dec 6th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||164.57||Analyst Rating||Moderate Buy 1.97|
|Potential %||12.43||Finscreener Ranking||★ 40.48|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★ 41.70|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★+ 54.16|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★+ 35.16|
|Price Range Ratio 52W %||41.51||Earnings Rating||Strong Buy|
|Market Cap||258.44B||Earnings Date||27th Oct 2023|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||2.85|
|EPS Growth Next 5 Years %||5.00|
|Avg. Weekly Volume||5.09M|
|Avg. Monthly Volume||5.03M|
|Avg. Quarterly Volume||4.62M|
AbbVie Inc. (NYSE: ABBV) stock closed at 146.38 per share at the end of the most recent trading day (a 1.25% change compared to the prior day closing price) with a volume of 4.78M shares and market capitalization of 258.44B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 50000 people. AbbVie Inc. CEO is Richard A. Gonzalez.
The one-year performance of AbbVie Inc. stock is -11.7%, while year-to-date (YTD) performance is -9.42%. ABBV stock has a five-year performance of 68.33%. Its 52-week range is between 130.9601 and 168.11, which gives ABBV stock a 52-week price range ratio of 41.51%
AbbVie Inc. currently has a PE ratio of 355.80, a price-to-book (PB) ratio of 18.42, a price-to-sale (PS) ratio of 6.66, a price to cashflow ratio of 13.10, a PEG ratio of 71.16, a ROA of 9.98%, a ROC of 17.00% and a ROE of 97.14%. The company’s profit margin is 21.83%, its EBITDA margin is 43.80%, and its revenue ttm is $42.93 Billion , which makes it $24.28 revenue per share.
Of the last four earnings reports from AbbVie Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.85 for the next earnings report. AbbVie Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for AbbVie Inc. is Moderate Buy (1.97), with a target price of $164.57, which is +12.43% compared to the current price. The earnings rating for AbbVie Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AbbVie Inc. has a dividend yield of 3.66% with a dividend per share of $5.92 and a payout ratio of 134.00%.
AbbVie Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 5.39, ATR14 : 2.38, CCI20 : 145.74, Chaikin Money Flow : 0.11, MACD : -0.24, Money Flow Index : 57.33, ROC : 4.55, RSI : 61.43, STOCH (14,3) : 89.99, STOCH RSI : 1.00, UO : 62.20, Williams %R : -10.01), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AbbVie Inc. in the last 12-months were: Azita Saleki-Gerhardt (Option Excercise at a value of $1 285 500), Azita Saleki-Gerhardt (Sold 25 000 shares of value $3 738 143 ), Carrie C. Strom (Option Excercise at a value of $872 949), Carrie C. Strom (Sold 28 541 shares of value $4 310 770 ), Elaine K. Sorg (Option Excercise at a value of $3 025 487), Elaine K. Sorg (Sold 30 323 shares of value $4 714 887 ), Jeffrey Ryan Stewart (Option Excercise at a value of $1 196 496), Jeffrey Ryan Stewart (Sold 53 125 shares of value $8 089 998 ), Perry C. Siatis (Option Excercise at a value of $1 061 372), Perry C. Siatis (Sold 10 884 shares of value $1 675 378 ), Richmond Timothy (Option Excercise at a value of $2 324 418), Richmond Timothy (Sold 86 511 shares of value $13 691 164 ), Roxanne S. Austin (Sold 10 000 shares of value $1 505 000 ), Saleki-Gerhardt Azita (Option Excercise at a value of $2 673 325), Saleki-Gerhardt Azita (Sold 61 990 shares of value $9 452 358 ), Scott T. Reents (Sold 15 942 shares of value $2 440 354 ), Sorg Elaine (Option Excercise at a value of $2 805 467), Sorg Elaine (Sold 58 955 shares of value $9 264 140 ), Stewart Jeffrey (Option Excercise at a value of $1 196 496), Stewart Jeffrey (Sold 53 125 shares of value $8 089 998 ), Strom Carrie (Option Excercise at a value of $872 949), Strom Carrie (Sold 28 541 shares of value $4 310 770 ), Timothy J. Richmond (Option Excercise at a value of $2 324 418), Timothy J. Richmond (Sold 42 370 shares of value $6 925 018 )
Tue, 31 Oct 2023 06:20 GMT Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), AbbVie (ABBV) and Merck & Company (MRK)- TipRanks. All rights reserved.
Mon, 25 Sep 2023 12:49 GMT I-Mab price target lowered to $23 from $24 at Needham- TipRanks. All rights reserved.
Wed, 13 Sep 2023 01:55 GMT AbbVie (ABBV) Gets a Hold from Goldman Sachs- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.